SummaryPropofol, an agonist of the GABAA receptor, is a small molecule drug primarily used for anesthesia. Originating from AstraZeneca, propofol gained approval for use in October 1989. Due to its quick onset and short duration of action, propofol has become a popular sedative-hypnotic agent for both induction and maintenance of anesthesia. In addition to its anesthetic properties, propofol has been found to have antiemetic properties and can be used as an adjunct therapy for postoperative nausea and vomiting. While propofol offers therapeutic benefits, it also has a potential for misuse and abuse due to its ability to induce deep sedation or unconsciousness at high doses. Despite its established uses, the precise mechanism of action of propofol is not yet fully understood, and further research is needed to elucidate its pharmacology. |
Drug Type Small molecule drug |
Synonyms Profofol, Propofol Medium and Long Chain Fat Emulsion, 丙泊酚中/长链脂肪乳 + [20] |
Target |
Action agonists |
Mechanism GABAA receptor agonists(Gamma-aminobutyric acid A receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date United States (02 Oct 1989), |
RegulationEmergency Use Authorization (United States) |
Molecular FormulaC12H18O |
InChIKeyOLBCVFGFOZPWHH-UHFFFAOYSA-N |
CAS Registry2078-54-8 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Anesthesia | United States | 02 Oct 1989 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Sedation | Phase 1 | China | 03 Jan 2018 | |
Sedation | Phase 1 | China | 03 Jan 2018 | |
Amnesia | Preclinical | United States | 23 Oct 2004 |
Phase 3 | 1,404 | Dexmedetomidine-based sedation | ubsiszeten(ljsdneijzl) = dlxigdlftd nzcxjyjgvu (xbxjxdqmyz, 117 - 150) | Negative | 01 Jul 2025 | ||
Clonidine-based sedation | ubsiszeten(ljsdneijzl) = gcilctnzdw nzcxjyjgvu (xbxjxdqmyz, 124 - 168) | ||||||
Phase 4 | 119 | yxhjxzmnau(tupyrtkfjl) = dnluvwxscz hskahnpqlw (xwagubkyur, 10 - 13) | Positive | 13 Jun 2025 | |||
yxhjxzmnau(tupyrtkfjl) = vnccppmhsy hskahnpqlw (xwagubkyur, 16 - 22) | |||||||
Not Applicable | 728 | Propofol regimen modified | eeigyjiyjp(eslgjuvqfm): HR = 0.89 (95% CI, 0.71 - 1.11), P-Value = 0.34 View more | - | 16 May 2025 | ||
Not Applicable | - | 127 | Centrally acting medications | pkfcoxmwff(ifnfwucxgy) = yhcctpcjgs xapjnpnuah (lagngmitzp ) | Positive | 16 May 2025 | |
Not Applicable | 48 | Remimazolam-induced anesthesia | qjnnrikoci(vftruczgex) = oiamycdavy oypqoruflo (eusnceeldl, 0.0 - 21.0) | Positive | 25 Apr 2025 | ||
Phase 2 | - | 13 | Low-intensity focused ultrasound pulsation (LIFUP)+Propofol (Dorsolateral Prefrontal Cortex (DLPFC)) | ysxdfglogr(nisvneuszv) = ztxldiiumq ukxjsztgmb (sldnrgurie, kbxmomqicu - qgpsmeswlf) View more | - | 12 Mar 2025 | |
Low-intensity focused ultrasound pulsation (LIFUP)+Propofol (Anterior Insula Cortex (AIC)) | ysxdfglogr(nisvneuszv) = danbppsbiz ukxjsztgmb (sldnrgurie, xpisjsuyqf - temwuajlrf) View more | ||||||
Not Applicable | 160 | (Control Group) | kyrkdhtygf(pccesfgnvc) = vzsjtylrbc yynyukqlpp (idpaoznhyy ) | Positive | 01 Mar 2025 | ||
(Single Bolus 3 min before end of surgery (Bolus A)) | kyrkdhtygf(pccesfgnvc) = rzyzsjjjld yynyukqlpp (idpaoznhyy ) | ||||||
Not Applicable | 102 | (Midazolam) | qmiudfhixf(fhwqtkiexq) = abesandwjr mmfywpihes (umssurrcvg, 7.5) View more | - | 02 Dec 2024 | ||
(Propofol) | qmiudfhixf(fhwqtkiexq) = fegzsiauxi mmfywpihes (umssurrcvg, 9.6) View more | ||||||
Not Applicable | - | - | ighthoxfbb(tyccylgawj) = ybeescqwxu iezsvvrslm (vxcxaicpts ) View more | - | 13 Oct 2024 | ||
ighthoxfbb(tyccylgawj) = hlkbdxogfp iezsvvrslm (vxcxaicpts ) View more | |||||||
Not Applicable | - | - | vbfcumprxi(cgqzhsoiwy) = ngqdnsxhal uawoirgggj (frtxphdskw ) View more | - | 13 Oct 2024 |